INZY
Price:
$4.98
Market Cap:
$312.42M
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
INZY
According to Inozyme Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -68.93%. This represents a change of 272.59% compared to the average of -18.50% of the last 4 quarters.
The mean historical ROE of Inozyme Pharma, Inc. over the last ten years is -12.37%. The current -68.93% ROE has changed 457.43% with respect to the historical average. Over the past ten years (40 quarters), INZY's ROE was at its highest in in the December 2019 quarter at 19.70%. The ROE was at its lowest in in the June 2024 quarter at -28.63%.
Average
-12.37%
Median
-35.32%
Minimum
-55.19%
Maximum
56.05%
Discovering the peaks and valleys of Inozyme Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual ROE = 56.05%
Minimum Annual Increase = -163.02%
Minimum Annual ROE = -55.19%
Year | ROE | Change |
---|---|---|
2023 | -50.66% | -8.20% |
2022 | -55.19% | 6.89% |
2021 | -51.63% | 46.18% |
2020 | -35.32% | -163.02% |
2019 | 56.05% | 11.67% |
2018 | 50.19% | Infinity% |
The current ROE of Inozyme Pharma, Inc. (INZY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-52.49%
5-year avg
-27.35%
10-year avg
-12.37%
Inozyme Pharma, Inc.’s ROE is greater than Day One Biopharmaceuticals, Inc. (-122.70%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Mereo BioPharma Group plc (-63.39%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than PDS Biotechnology Corporation (-137.06%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Eledon Pharmaceuticals, Inc. (-124.74%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%),
Company | ROE | Market cap |
---|---|---|
-122.70% | $1.25B | |
32.93% | $109.78M | |
-24.63% | $133.38M | |
-63.39% | $664.26M | |
-39.58% | $549.60M | |
-137.06% | $107.88M | |
-51.77% | $159.50M | |
-124.74% | $100.73M | |
-46.15% | $161.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inozyme Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inozyme Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Inozyme Pharma, Inc.'s ROE?
How is the ROE calculated for Inozyme Pharma, Inc. (INZY)?
What is the highest ROE for Inozyme Pharma, Inc. (INZY)?
What is the 3-year average ROE for Inozyme Pharma, Inc. (INZY)?
What is the 5-year average ROE for Inozyme Pharma, Inc. (INZY)?
How does the current ROE for Inozyme Pharma, Inc. (INZY) compare to its historical average?